About Recipharm
Recipharm is a company based in Jordbro (Sweden) founded in 1995 was acquired by Nichepharm in July 2024. Recipharm has completed 8 acquisitions, including Arranta Bio, Consort Medical and Flamel Technologies. Recipharm offers products and services including ReciBioPharm Services, Sterile Fill and Finish, and Solids Manufacturing. Recipharm operates in a competitive market with competitors including Akums, Jubilant Life Sciences, Unither, Nectar Lifesciences and CoreRx, among others.
- Headquarter Jordbro, Sweden
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Recipharm Ab
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
EQT
& 1 more
-
Employee Count
Not available
-
Investments & Acquisitions
Arranta Bio
& 7 more
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Recipharm
Recipharm offers a comprehensive portfolio of products and services, including ReciBioPharm Services, Sterile Fill and Finish, and Solids Manufacturing.
Development and GMP manufacture of ATMPs and viral vectors
Aseptic filling for vials, syringes, and lyophilisation processes
Development and manufacturing of tablets, capsules, and liquids
People of Recipharm
Unlock access to complete
Unlock access to complete
Software Development Team
71 people
Leadership Team
17 people
Human Resources and Administration
17 people
Sales and Marketing
13 people
Head Team
13 people
Finance and Accounting
9 people
Operations Team
6 people
Product Management Team
6 people
Unlock access to complete
Funding Insights of Recipharm
Detailed funding history for Recipharm
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Recipharm
Recipharm has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include EQT and Nichepharm.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
EQT is recognized as a global investment organization focused on value creation.
|
Locked | Locked | Locked | |
|
Injectable pharmaceuticals are developed and manufactured by Nichepharm.
|
Locked | Locked | Locked |
Investor details for Recipharm
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Recipharm
Recipharm has strategically engaged in corporate development activities, having acquired 8 companies. Notable acquisitions include Arranta Bio, Consort Medical and Flamel Technologies.
Investment portfolio details for Recipharm
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of therapeutics for microbiome based diseases
|
Locked | Locked | 2019 | Locked | |
|
CDMO offering development, cGMP manufacturing and fill/finish of biologics based on viruses and bacteria
|
Locked | Locked | 2007 | Locked | |
|
Microbial and mammalian-derived products are developed and manufactured by GenIbet.
|
Locked | Locked | 2006 | Locked |
Complete acquisition details for Recipharm
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Recipharm
Detailed financials for Recipharm
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Recipharm Comparisons
Peer comparison for Recipharm
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Recipharm
Recipharm operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Akums, Jubilant Life Sciences, Unither, Nectar Lifesciences and CoreRx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
CDMO focusing on spectrum of dosage forms and therapeutic segments
|
|
| Locked | Locked | Locked |
Company offering a suite of R&D and manufacturing services for small molecules and generics
|
|
| Locked | Locked | Locked |
Contract development and manufacturing organization for proprietary and generic drugs
|
|
| Locked | Locked | Locked |
Cephalosporin APIs and generic formulations are manufactured.
|
|
| Locked | Locked | Locked |
CDMO with a focus on early phase drug product development
|
Detailed competitors of Recipharm
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Recipharm
Complete news archive for Recipharm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Recipharm
Recipharm was founded in 1995.
Recipharm is headquartered in Jordbro, Sweden.
Greg Behar is the current CEO of Recipharm.
Recipharm operates as a pharmaceutical contract development and manufacturing company (CDMO). Its dosage forms include solid dose, sterile, semi solids, beta-lactams, hormones, dry powder inhalers, granulates, and powders. It provides pharmaceutical development services, such as formulation development, clinical supplies, analytical development, stability studies, packaging development and selection, and raw material selection; and manufacturing services, also offering EU gateway release and testing, regulatory, stability studies, and customized services. It has manufacturing facilities in Sweden, France, and the United Kingdom.
Recipharm's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.
Recipharm offers ReciBioPharm Services, Sterile Fill and Finish, and Solids Manufacturing.
Recipharm has made 8 acquisitions, including Arranta Bio, Consort Medical, and Flamel Technologies.
Recipharm has 2 investors. Key investors include EQT, and Nichepharm.